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Abstract
The endothelium is an organ with a key role in the maintenance of cardiovascular 
health through the regulation of vascular tone, vascular resistance, blood flow, 
and arterial pressure. These functions are related with the synthesis and release of 
vasoactive molecules, mainly vasodilators like nitric oxide (NO) and endothelium-
derived hyperpolarizing factor (EDHF). Both factors are released and diffused from 
endothelial cells to the smooth muscle cells, where there is a subsequent activation 
of signaling pathways that finally decrease the intracellular calcium to induce the 
vascular relaxation. The study of the molecular mechanisms that underlie the 
endothelial function still is in development, but from the evidence obtained from 
the endothelial cells in vitro studies are possible to partially describe the pathways to 
regulate the physiological endothelial function and the disturbances in pathological 
conditions. In this mini-review, we describe the main mechanisms for NO synthesis 
and the role of potassium channels related with EDHF. We include schemes and 
graphical summaries for better understanding of the molecular regulation of vascular 
tone in the human cardiovascular system.
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1. Characteristics of the endothelium
The endothelial cells (ECs) have mesenchymal origin, length of 25–50 μm and 
form a flat epithelium called endothelium. The endothelium in a human adult is 
composed of approximately 1–6 × 1013 cells, constituting an organ that weighs 
approximately 1 kg and covers a surface area of approximately 1–7 m2 [1]. For 
decades, the endothelium was considered as a simple barrier between blood and the 
rest of the body’s tissues. However, since the early 1980s, this vision changed radi-
cally [2] and, today, the endothelium is considered a true organ that fulfills multiple 
functions in the physiology and pathophysiology of vascular system, including 
autocrine, paracrine, and endocrine actions and the regulation of coagulation and 
fibrinolysis processes [3].
One of the most important functions of endothelial cells is their participation in 
the regulation of vascular tone. In the classic article of Furchgott and Zawadzki in 
1980, it was demonstrated that the presence of the endothelium is essential for the 
vasodilator effect induced by acetylcholine in isolated blood vessels pre-constricted 
with norepinephrine. In those years, it was proposed that the vasodilation was 
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produced through a factor that was released by the endothelium in response to 
agonists [4]. This factor was called the endothelial-derived relaxing factor (EDRF) 
[5]. Between 1986 and 1990, it was concluded that this factor corresponded to nitric 
oxide (NO) [6, 7]. The endothelium responds to mechanical stimuli such as pres-
sure and flow stress (“shear stress”), hormonal stimuli, and vasoactive substances 
that regulate the vascular tone. The endothelial cells release molecules that regulate 
vasomotor function, inflammation, and hemostasis. Vasodilators agents include 
NO, prostacyclin, and endothelium-derived hyperpolarizing factor (EDHF). 
Vasoconstrictors agents include endothelin 1, angiotensin II, thromboxane A2, and 
reactive oxygen-derived species (ROS). Inflammatory mediators include NO, inter-
cellular adhesion molecule 1 (ICAM-1), vascular adhesion molecule 1 (VCAM-1), 
E-selectin, and NFκB (Figure 1 [8]).
Since the discovery of NO, the mechanisms of endothelial cell activation 
and endothelial dysfunction have been studied. In this way, the quiescent endothe-
lial cells express a vasodilator, anticoagulant, and anti-adhesive phenotype, 
while the activated endothelial cell expresses procoagulant, pro-adhesive, and 
vasoconstrictive properties [9]. It has been considered that the decrease in 
the capacity of the vascular endothelium to stimulate vasodilation generates 
endothelial dysfunction, a phenomenon that is observed in several pathologi-
cal conditions such as hypertension, hypercholesterolemia, diabetes mellitus, 
hyperhomocysteinemia, chronic kidney failure, chronic heart failure, etc. 
Although the molecular basis for endothelial dysfunction is not fully under-
stood, numerous studies point to decreased biosynthesis and/or NO activity as 
a central mechanism [10–13].
Figure 1. 
Vascular tone regulation. The vascular tone is partially regulated by the local factors secreted by endothelial 
cells (ECs) in response to physical factors like shear stress and humoral and chemical factors like hormones and 
oxygen levels. The changes in blood flow are detected by membrane proteins, mainly receptors (Rs), transporters 
(Ts), and ion channels (ICs). There is a network connecting the activities of these proteins through signaling 
pathways that induce the release of different mediators like thromboxane A2 (TxA2), endothelin 1, reactive 
oxygen species (ROS), nitric oxide (NO), endothelium-derived hyperpolarizing factor (EDHF), or prostacyclin 
(PGI2), among others. The equilibrium between the vasoconstrictors and vasodilators factors maintains the 
endothelial function and vascular health.
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2. Synthesis of nitric oxide in the endothelium
NO is synthesized from the semi-essential cationic amino acid L-arginine, which 
must be transported from the extracellular space into the endothelial cell by a family 
of cationic amino acid transporters (CATs) [14]. This amino acid is the substrate in 
a reaction where the metabolic product corresponds to L-citrulline in an equimolar 
proportion with the coproduct NO [15, 16]. This reaction is catalyzed by the enzyme 
NO synthase (NOS), which can be classified into their constitutive forms (cNOS) 
and their inducible form (iNOS) [17]. The cNOS includes the endothelial isoform 
(eNOS) and the neuronal isoform (nNOS), both producing NO in short bursts at low 
concentrations (nM) and in a calcium-dependent manner to fulfill the physiological 
functions of NO. The physiological activity of eNOS is dependent on several cofactors 
and is regulated by signaling pathways that induce phosphorylation in different sites 
for activation (serine 1177) or inhibition (threonine 495) [17]. NO diffuses from 
endothelial cells to smooth muscle cells (SMCs) and activates the soluble guanylate 
cyclase (sGC) pathway, to reduce the intracellular calcium and induce vasodilation 
(Figure 2). iNOS is mainly expressed in cells that participate in the inflammatory 
response after induction by cytokines and other inflammatory mediators, producing 
NO in high concentrations (μM) and independently of calcium [18–20].
The availability of NO in vivo is regulated by a combination of NO synthesis and 
inactivation. The decrease in the availability of NO may be due to a lower expression 
Figure 2. 
L-arginine transport and nitric oxide synthesis in endothelial cells. hCAT-1 is a protein expressed in plasma 
membrane of endothelial cells, mainly in plasma membrane invagination called caveolae. The L-arginine 
enters to the cell from blood and is used by eNOS to synthesize L-citrulline and nitric oxide (NO). The eNOS 
needs different cofactors to maintain its function, which include tetrahydrobiopterin (BH4), nicotidamine 
adenine dinuclotide phosphate (NADPH), and heat shock protein 90 (Hsp90). Nitric oxide diffuses through 
the cell membranes and enters the smooth muscle cells to activate the soluble guanlylate cyclase (sGC). The sGC 
synthesizes cyclic GMP (cGMP), which activates protein kinase G and, after subsequent steps, the intracellular 
calcium decreases to induce the vasodilation.
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or activity of eNOS, as a result of the action of endogenous and exogenous inhibitors 
or due to the lower availability of the substrate L-arginine [8, 14]. The availability of 
NO can also be diminished by the rapid reaction between NO and reactive oxygen-
derived species (ROS) [13].
3. Reactive oxygen-derived species (ROS) in endothelium
Endothelial cells generate ROS, including the superoxide radical (O2
.−), hydrogen 
peroxide (H2O2), peroxynitrite (ONOO
−), hydroxyl radical (.OH), among others 
[15, 16]. In endothelial cells, the main sources of ROS are the enzymatic complex 
xanthine oxidoreductase (XOR) [17], the complex of membrane nicotinamide 
adenine dinucleotide phosphate oxidase (NADPH oxidase) [18], eNOS itself when it 
is “uncoupled” due to lack of tetrahydrobiopterin (BH4) or L-arginine [19], mito-
chondrial cytochromes [20], and hemoglobin [21].
Among all endothelial ROS sources, NADPH oxidases are enzymes whose 
primary function is the generation of ROS and they play an important role in redox 
signaling [22]. On the other hand, the activity of NADPH oxidase can cause the 
uncoupling of eNOS by the oxidative degradation of BH4, leading to the eNOS-
dependent synthesis of O2
·− and detriment of the synthesis of NO [18, 23]. Once 
O2
·− is synthesized, it can act as a precursor to other ROS due to its use by superoxide 
dismutase (SOD) to generate H2O2 that has greater stability and capacity to cross 
biological membranes, and it therefore can act as a modulator of signal transduc-
tion pathways [24]. Furthermore, O2
·− reacts quickly with NO to generate ONOO−, 
a powerful oxidizing agent that causes DNA fragmentation and lipid oxidation [25].
It is currently postulated that the mechanism by which O2
·− “kidnaps” NO 
would play a central role in the development of endothelial dysfunction that is 
seen in pathologies such as diabetes mellitus [26–28], preeclampsia [29, 30], and 
hypertension [31].
4. L-arginine transport in human fetal endothelium
The amino acid L-arginine is taken up by endothelial cells through the trans-
porter systems y+, y+L, b0,+, and y B0,+ [32–35]. Of these systems, there are two that 
have been described in HUVEC, that is, y+ system [36–38] and y+L system [39]. 
The y+ system family is currently known to include at least five cationic amino acid 
transporters (CATs) called CAT-1, CAT-2A, CAT-2B, CAT-3, and CAT-4. CAT-1 is 
expressed ubiquitously, CAT-2A and CAT-3 are constitutively expressed in liver and 
brain, respectively, while CAT-2B is induced in a variety of cell types in response to 
bacterial endotoxins and pro-inflammatory cytokines [40, 41]. CAT-4 corresponds to 
a cDNA sequence with 41–42% identity with the other members of the CATs family, 
but its transport activity has not yet been determined [32, 34, 35]. CAT-1, CAT-2B, 
and CAT-3 are characterized by high affinity to the substrate (Km = 100–400 μM) 
and independency of Na+, while CAT-2A has low affinity for cationic amino acids 
(Km = 2–5 mM). Two members of CATs have been reported to be expressed in 
HUVEC, that is, hCAT-1 and hCAT-2B, while hCAT-2A and hCAT-3 transport-
ers have not been detected in this cell type [34, 36–39] (Table 1). Although the 
hCAT-1 and hCAT-2B transporters have similar kinetic characteristics, it is possible 
to differentiate them by their different sensitivities to L-lysine trans-stimulation. 
In Xenopus laevis oocytes injected with hCAT-1 and hCAT-2B mRNA, L-lysine 
increases L-arginine transport by 9.8-fold and 1.8-fold, respectively [42]. Thus, for 
L-lysine trans-stimulation assays in HUVEC, it has been possible to determine that 
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the hCAT-1 transporter accounts for 60–80% of the total uptake of L-arginine in 
physiological conditions [36–38]. The importance of the hCAT-1 transporter in NO 
synthesis has been confirmed through a transgenic mouse model that overexpresses 
the protein exclusively in the endothelium. Aortic rings obtained from these trans-
genic mice have a higher sensitivity to relaxation in response to acetylcholine com-
pared to native mice, while endothelial cell cultures obtained from these animals, 
that overexpress hCAT-1, exhibit a greater NO synthesis [43].
5. Regulation of the expression of hCAT-1
Regarding the gene organization of CAT transporters, it is known that the SLC7 
family is phylogenetically composed of two subfamilies formed by cationic amino 
acid transporters (CATs) and glycoprotein-associated amino acid transporters 
(HATs). The cationic amino acid transporter family is encoded by the SLC7A (1–4) 
genes and corresponds to proteins with 14 transmembrane domains [44]. Specifically, 
the gene that encodes the hCAT-1 protein corresponds to SLC7A1 whose open reading 
frame is formed by 11 exons and 10 introns. The gene is located on chromosome 
13q12-13q14 [45].
Among the genes encoding CAT-1 in rat, mouse and human have common char-
acteristics: the promoter region lacks TATA box, and they have multiple binding 
sites for the transcription factor specific protein 1 (Sp1) and they have an extensive 
3′ non-translatable region (3′UTR) that could perform functions in the regulation 
of mRNA stability or in translation [46–49]. In rats, stress by amino acids depriva-
tion induces an increase in the rCAT-1 mRNA expression by a mechanism related 
to increased mRNA stability [46]. This increased mRNA stability would be related 
to the presence of a regulatory region within the 3′UTR sequence of the gene [47]. 
Subsequent experiments have shown that the effect of amino acids deprivation on 
rCAT-1 expression would depend on both transcriptional [48] and posttranscrip-
tional mechanisms [50].
In humans, it is known that insulin increases leg blood flow in healthy subjects 
via stimulation of endothelial NO synthase (eNOS) [51]. Insulin also increases the 
synthesis and release of NO and release in primary cultures of HUVEC [38, 52]. 
Biological effects of insulin involve activation of several transcription factors, includ-
ing Sp1 in several cell types [53, 54]. Insulin increases Sp1 nuclear protein abundance 
and its binding to a proximal region (−177 and −105 bp from ATG) of the SLC7A1 
promoter containing four consensus sequences for Sp1 [55]. Interestingly, in 
patients with essential hypertension, a reduction of SLC7A1 transcriptional activ-
ity due to reduced Sp1 activity in the promoter region has been reported [12]. So, 
the transcriptional regulation of SLC7A1 is relevant for cardiovascular physiology, 
Gene Protein Km (μM) Distribution
SLC7A1 CAT-1 70–250 All tissues except liver and lacrimal gland
SLC7A2 CAT-2A 2.2–5.2 Liver, skeletal muscle, and pancreas
SLC7A2 CAT-2B 38–380 Endothelium, and inducible in several tissues
SLC7A3 CAT-3 40–120 Thymus, ovary, testes, and brain
SLC7A4 CAT-4 — Brain, testes, and placenta
Proteins CATs are coded in different genes (except CAT2A and 2B, same gene), have different kinetic constants for 
the transport of L-arginine (Km) and distribution in tissues.
Table 1. 
CATs’ family members.
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and the reduction of the promoter activity of this gene could be associated with 
cardiovascular disease (CVD).
On the other hand, the first intron of SLC7A1 may play a bifunctional role in 
regulating the SLC7A1 transcriptional activity by the binding of the purine-rich 
element binding protein A (Pur alpha) in physiological conditions and by activating 
the transcription factor 4 (ATF4) in endoplasmic reticulum stress or by decreasing 
the SLC7A1 transcriptional activity by the C/EBP homologous protein 10 (CHOP) 
binding in C6 rat glioma cells [56].
For the physiological regulation of hCAT-1 activity, both transcriptional regula-
tion of SLC7A1 and/or posttranscriptional regulation of SLC7A1 transcript are 
relevant for the protein expression and L-arginine transport [55]. Insulin increases 
the expression of SLC7A1 gene due to an increased transcriptional activity, most 
likely due to higher Sp1 activity. So, hCAT-1 expression and activity are regulated by 
insulin in endothelium, suggesting that in insulin resistance there is a reduction of 
L-arginine transport and NO synthesis that contributes to endothelial dysfunction 
and cardiovascular diseases.
6.  High D-glucose and expression and activity of L-arginine/NO 
pathway
Hyperglycemia and diabetes mellitus are pathological conditions associated 
with fetal endothelial dysfunction [55] and type 2 diabetes mellitus (T2DM) [57] 
or cardiovascular disease (CVD) [58]. CVD in patients with diabetes mellitus is 
associated with the generation of ROS.
High concentration of D-glucose (25 mM) increases L-arginine transport 
and cGMP accumulation in endothelium in a similar manner to that observed in 
HUVEC from pregnancies with gestational diabetes [33, 59]. Increased L-arginine 
transport in response to incubation with high D-glucose has been related to 
increased mRNA levels for the hCAT-1 and eNOS activity in HUVEC [60]. In 
human aortic endothelial cells, prolonged incubation (7 days) with 25 mM 
D-glucose induces a decrease in eNOS activity (determined by nitrite content), 
protein abundance, and mRNA level. This effect is associated with a decrease in 
eNOS promoter activity [61]. In bovine aortic endothelial cells (BAECs), there 
is a lower production of insulin-induced NO when the cells were incubated with 
high extracellular concentration of D-glucose, an effect that seems to depend on a 
signaling pathway that involves to the type 1 insulin receptor (IR-1), phosphatidyl 
inositol 3 kinase, and the inhibitor of nuclear factor kappa-B kinase [62]. On 
the other hand, the increase of cGMP production induced by high D-glucose in 
HUVEC is blocked by incubating the cells with 1 nM insulin [63]. Incubation with 
1 nM insulin (8 h) has been shown in this same cell type to be sufficient to block 
the effect that D-glucose has on the decreased transport of adenosine [64], an 
important vasoactive nucleoside [65].
In HUVEC, high extracellular D-glucose increases L-arginine transport, NO 
synthesis, and O2
.− generation through eNOS and NADPH oxidase activation. 
Additionally, high D-glucose increased the contractile response in the human 
umbilical vein. Insulin reversed these effects of high D-glucose, leading to normal 
hCAT-1 expression, NO synthesis, ROS generation, and vascular tone. Insulin acts 
like antioxidant molecules (like tempol, ascorbic acid) to restore high D-glucose-
increased oxidative stress in the fetoplacental vascular bed [66]. High D-glucose 
increases L-arginine transport, likely resulting from higher hCAT-1 expression and 
protein abundance in the plasma membrane. This mechanism could be an adap-
tive response of HUVEC to higher ROS generation from high D-glucose-activated 
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NADPH oxidase. In parallel, high D-glucose increased NO synthesis. Insulin reversed 
the high D-glucose-mediated alterations in L-arginine transport involving the 
modulation of SLC7A1 gene expression, leading to altered umbilical vein reactivity. 
Modulation of hCAT-1 expression and activity by insulin is the key to maintaining 
umbilical vein tone and endothelial function in physiologic and pathophysiological 
conditions (Figure 3) [66].
7. Role of potassium channels in endothelial function
Another important mechanism that regulates the endothelial function is the 
activity of ion channels that modulate the cell membrane potential. The calcium-
activated potassium channels (KCa) have been shown to be relevant to induce 
the necessary hyperpolarization to stimulate the relaxation of vascular smooth 
muscle cells (related with EDHF). In systemic circulation, large conductance 
KCa (BKCa) channels have been shown preferentially expressed in VSMC, mean-
while small (SKCa) and intermediate (IKCa) conductance KCa are preferentially 
expressed in endothelium [67, 68]. However, potassium currents inhibited by 
iberiotoxin (BKCa inhibitor) have been described in HUVEC stimulated by 
sildenafil or insulin [69]. In fact, insulin (10 nM) can directly activate native and 
recombinant BKCa currents in cell-attached patch-clamping experiments with a 
rapid effect that is MAPK-dependent when the hormone was added in the pipette 
[70]. There is evidence that insulin may induce endothelial cell hyperpolariza-
tion by modulating K channels activity [38, 71]. The insulin-induced relaxation 
in human placental veins (~368 μm diameter), pre-constricted with U46619, is a 
mechanism dependent on the BKCa channel activity. The co-incubation of vessels 
with genistein (tyrosine kinases inhibitor) and wortmannin (PI3K inhibitor) did 
not block the insulin’s relaxation, and by contrast potentiated the insulin-induced 
Figure 3. 
Endothelial dysfunction induced by high D-glucose and protection by insulin in HUVEC. Exposure of HUVEC 
to high D-glucose leads to an increase (↑) in the plasma membrane abundance of the human cationic amino 
acid transporter 1 (hCAT-1) and higher L-arginine uptake. High D-glucose activates NADPH oxidase, leading 
to higher generation of ROS, including O2
.−. Insulin restores ROS and O2
.− generation to values in cells exposed 
to 5 mM D-glucose (normal), resulting in the restoration of hCAT-1-mediated L-arginine transport and 
nitric oxide (NO) synthesis. High D-glucose and insulin also activate the SLC7A1 promoter region (coding for 
hCAT-1) up to −650 bp from the ATG via a mechanism involving ROS and O2
.− generation. In addition, insulin 
restores hCAT-1 protein abundance and its distribution in the cells via an NADPH oxidase-independent 
mechanism (data from González et al. [66]).
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vasodilation. Also, insulin decreased perfusion pressure (34 ± 3%) in the isolated 
cotyledon of normal placenta with a basal perfusion pressure of 64 ± 5 mmHg (or 
pre-constricted with U46619) [72]. The effects of insulin on BKCa activity are 
associated with evidences that show that the constriction induced by U46619 and 
H2O2 in placental vasculature is partially decreased with 10 nM insulin preincuba-
tion (10 min) in a mechanism totally dependent of BKCa activity [72]. Recently, 
it has been determined that insulin-mediated NO synthesis requires the participa-
tion of both IKCa/ BKCa channels and eNOS activity in HUVECs [71]. In the same 
cell type, insulin increased the open probability (NPo) of BKCa, associated with 
hyperpolarization in single cell analysis [69]. In human placental arteries, the 
relaxation induced by the NO donor, SNAP, is partially blocked by charybdotoxin 
(BKCa inhibitor) and almost totally blocked by charybdotoxin and ODQ (sGC 
inhibitor) [73]. Therefore, an extracellular stimulus that increases the NO avail-
ability activates a mechanism that involves sGC and BKCa activities [71]. These 
findings constitute evidence for postulating a new mechanism induced by insulin 
in human vasculature related with the physiological regulation of KCa activity for 
NO synthesis (Figure 4).
8. Final remarks
The relevance of the endothelium for cardiovascular physiology is well estab-
lished, mainly by findings related to the capacity of endothelial cells to synthesize NO 
and regulate the plasma membrane potential of smooth muscle cells. Figure 5 shows 
a graphical summary of the L-arginine/NO pathway in the human blood vessels that 
highlight the capacity of endothelial cells to respond to extracellular stimuli and 
translate the mechanical forces and endocrine signals to intracellular mechanisms 
leading to NO synthesis and activation of potassium channels. It is important to note 
that the subcellular distribution of hCAT-1 and eNOS is also relevant for endothelial 
cells function. In physiological state, hCAT-1 colocalizes with caveolin-1 in the 
plasma membrane caveolae in proximity to eNOS.
Figure 4. 
Proposal of mechanism for KCa activation by insulin. Evidence obtained in endothelial cells (ECs) shows that 
insulin activates KCa (mainly BKCa) in a mechanism still not fully understood. The activation of KCa by 
insulin induces hyperpolarization (↑ΔV), leading to activation of eNOS for NO synthesis from L-arginine 
uptake by hCAT-1 (modified from Rojas et al. [71]).
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Role of endothelium in the regulation of vascular tone. Endothelial cells, as a part of blood vessels walls, 
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is relevant for its function, and the role of potassium channels (BKCa, mainly) has been recently described as 
important for endothelial cells function. The activity of the endothelium is regulated by different agonists like 
acetylcholine (Ach) through plasma membrane receptor (AchR) and others like insulin or serotonin, etc.
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